Moderna is scaling back R&D investment in new vaccine Phase 3 trials as U.S. regulatory and policy headwinds reduce commercial viability, CEO Stéphane Bancel said in an interview with Bloomberg TV at the World Economic Forum in Davos.
#MRNAStock #Moderna#Vaccines #Biotech #Trump
1
0
0
0